Our CSO, Lars Johansson will be speaking later this week at the Innovation in Obesity Therapeutics Summit. His talk ‘Underneath the lost kilos: imaging in obesity and metabolic disease drug development’ will go into some of the body composition, muscle, and organ-related insights that ban be captured using imaging in clinical trials.
More specifically, the talk will cover:
- Imaging methodologies like magnetic resonance imaging (MRI) and dual-energy x-ray absorptiometry (DXA or DEXA) provide information about different aspects of body composition meeting different needs in clinical trials
- Body composition assessment of muscle and adipose tissue can be combined with measures of other end-organ effects for a deeper understanding of treatment responses
- MRI-based methods can also provide detailed insights into muscle composition including inter- and intramuscular fat (IMCL, EMCL), glycogen, sodium and functional readouts
To hear more, join us at the West Coast Innovation in Obesity Therapeutics Summit on Wednesday, December 11 at 11:00 PST to hear Lars’ talk. The Summit takes place from December 10-12 in San Diego, CA.